Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0153690 (bone metastases)
 6,382 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Fifteen patients with widespread painful osseous metastases from breast cancer unresponsive to other systemic therapy were treated with mithramycin at dose levels usually used for treating Paget's disease. Ten patients had relief of pain, which was marked and rapid in onset in seven. Mobility was greatly improved in four patients. Healing of bone lesions did not occur and new lesions developed while treatment was being given. Clinical response was associated with a decrease in plasma alkaline phosphatase. Toxicity was mild and consisted of nausea in most patients and a slight decrease in platelet count in one patient. Mithramycin is a useful agent for palliation of painful bone metastases and should be considered for further trials of combination chemotherapy for advanced breast cancer with bone metastases.
 ...
PMID:Effect of mithramycin on widespread painful bone metastases in cancer of the breast. 9 11

A significant correlation between the activity of the bone isoenzyme or serum alkaline phosphatase and the urinary hydroxyproline excretion in osteomalacia, osteoporosis, primary hyperparathyroidism with osteodystrophy, Paget's disease, secondary bone tumours, and in a control group was found (P less than 0.001). This close correlation was not observed between these variables in patients with active acromegaly. Diagnosis determined from these indices of formation and turnover of bone matrix agreed with that established by histological and histochemical examination of bone, by X-ray investigation of the skeleton, and by the radionuclear 85Sr test. The relationship between the activity of bone isoenzyme and urinary hydroxyproline excretion differed in metabolic bone diseases with a high bone turnover, in patients with osteoporosis and in patients with early osteoclastic bone metastases.
 ...
PMID:Relationship of the activity of the bone isoenzyme of serum alkaline phosphatase to urinary hydroxyproline excretion in metabolic and neoplastic bone diseases. 10 9

The intravenous application of 89-strontium for the relief of pain in 43 patients with breast cancer, bronchogenic cancer, carcinoma of the prostate, hypernephroma and lymphoma with generalized bone metastases is reported. A remarkable clinical improvement was achieved in 33 (76.7%) patients. In four patients a transient analgesic effect was observed. In six cases no response could be achieved. The therapeutic effect usually was long-lasting. At the same time, an increase of alkaline phosphatase was observed, which was interpreted as an indication for the stimulation of osteoblasts and osteoid peripheral zones owing to beta-emission of the radioisotope in the affected areas. There was a significant correlation between the concentration of 85Sr in the bone scan and the therapeutic result of 89Sr-therapy. The indication for such therapy and possible late adverse effects of bone-seeking isotopes are discussed.
 ...
PMID:[Endo-osseous isotope therapy of malignant skeletal disease (author's transl)]. 14 38

An essential part of the classification of prostate carcinoma is the diagnosis of bone metastases. This was done with 70 patients using x-ray analysis, scintography, determination of the acid and alkaline phosphatase, and pelvic crest biopsy, as well as aspiration of the pelvic and sternal bone marrow. In addition, the hydroxyproline concentration was determined in the 24-hour-urine. The study, which was initially undertaken on a sample group (n = 145), yielded a high correlation between age and sex and hydroxyproline values. Women before menopause show significantly lower values than do men of the same age. The data on patients with prostata cancer (n = 70) showed that patients with and without bone metastases, who had been treated with estrogens, had a significantly lower quantity of hydroxyproline than did patients who had not received estrogen therapy. Patients with skeletal metastases (n = 24) showed significantly higher hydroxyproline excretion in the urine than did those with prostate cancer without metastases, or healthy men of the same age (n = 35). Comparison of the results of hydroxyproline determination with the other diagnostic methods for demonstrating bone metastases showed that hydroxyproline determination was diagnostically on par with the scintigram. Pelvic crest biopsy, pelvic and sternal marrow aspiration can be considered valuable supplementary diagnostic procedures.
 ...
PMID:Urinary hydroxyproline in healthy patients and in prostate patients with and without bone metastases. 44 76

A 42-year old male was found to have adenocarcinoma of the lung and very high serum alkaline phosphatase levels. The clinical course and autopsy excluded the possibility that the enzyme elevation was due to liver or bone metastases, which is the most common cause for such a phenomenon. It was proven that the tumor secreted the alkaline phosphatase, and that the latter could serve as a marker of its recidivation. Although the phenomenon of tumors secreting alkaline phosphatase is not new, including some types of lung carcinomas (such as squamous cell and epidermoid), it is, to the best of our knowledge, the first time adenocarcinoma of the lung was found to secrete the enzyme.
 ...
PMID:Adenocarcinoma of the lung secreting alkaline phosphatase. 51 43

Distribution patterns of metastatic bone disease in 62 patients with soft-tissue cancers showed that 60% of bone lesions were located in the axial and 40% in the appendicular skeleton. Thirteen percent of the lesions were in appendicular regions not usually included in routine imaging studies. The majority of the metastatic skeletal lesions were clinically asymptomatic. The serum alkaline phosphatase level is a poor indicator of early bone metastases.
 ...
PMID:Distribution pattern of metastatic bone disease. A need for total body skeletal image. 57 63

The results of determination of the activity of the liver and bone serum alkaline phosphatase isoenzyme were in complete agreement with the clinical, laboratory and gamma-radiographic findings in all 62 examined patients with neoplastic liver metastases and with the same findings in 36 out of 38 patients with bone metastases. Determination of the bone isoenzyme concurred with the radionuclear findings in 27 out of 30 patients. Thermostable serum alkaline phosphatase variants were evaluated in 136 patients. They were found in 8 out of 40 patients with a lung carcinoma and in 8 out of 13 with a primary hepatocellular carcinoma. The findings were correlated with the presence of alpha-1 fetoprotein in the serum. A thermostable variant corresponding to the Nagao isoenzyme was evaluated biochemically in a patient with a stomach carcinoma.
 ...
PMID:Alkaline phosphatases in neoplastic diseases. 61 60

Bone marrow acid phosphatase has been reported to be a sensitive indicator of early bony metastasis from adenocarcinoma of the prostate. In order to evaluate this hypothesis, we measured bone marrow acid and alkaline phosphatase, lactic dehydrogenase, and calcium levels in a group of 84 patients with a variety of problems, including 18 with cancer of the prostate. We found that the bone marrow acid and alkaline phosphatase and lactic dehydrogenase were elevated and calcium was depressed in most patients. Among patients with prostate cancer, bone marrow acid phosphatase was not significantly different between those with or without bone metastases. In addition, the patients with prostatic cancer did not have higher levels of bone marrow acid phosphatase than subjects with other malignant and nonmalignant conditions. The level of acid and alkaline phosphatase, lactic dehydrogenase and calcium varied predictably with the aspiration technique used and was independent of sex, disease state or method of chemical determination. Due to this variation, we believe that bone marrow enzyme and calcium levels are of no value in the detection of metastases in patients with prostate cancer.
 ...
PMID:Lack of usefulness of bone marrow enzymes and calcium in staging patients with prostatic cancer. 63 3

We have observed creatine kinase isoenzyme BB in the sera of nine of 19 patients with Stage D carcinoma of the prostate. Its presence does not seem to correlate with acid phosphatase activity in serum or the presence of bone metastases as indicated by increased alkaline phosphatase activity in serum. Only three of the nine patients with BB isoenzyme activity detectable in their serum had abnormal values for total creatine kinase activity, but all had abnormal values for alkaline and acid phosphatase activity. All 10 patients with no BB isoenzyme detectable had abnormal acid phosphatase values; however, only seven had increased alkaline phosphatase values and only one had increased creatine kinase activity.
 ...
PMID:Presence of creatine kinase BB isoenzyme in some patients with prostatic carcinoma. 90 21

In 181 consecutive patients with breast cancer, urinary hydroxyproline excretion has been critically evaluated in conjunction with clinical, biochemical, radiological and scintigraphic parameters. The urinary hydroxyproline/creatinine ratio is a sensitive index of the presence of bone metastases. Urinary hydroxyproline excretion is a reliable method of selecting those patients whose elevated serum alkaline phosphatase is secondary to bone disease rather than liver idsease. The estimation of hydroxyproline excretion furthermore gives information on the activity of bone metastasis, and its response to treatment, which cannot be given by radiological or scintigraphic methods. It is doubtful whether urinary hydroxyproline estimation will help to detect bone metastases before they are apparent on scintigrams. When the bone scan is doubtful, as often occurs in older subjects, hydroxyproline excretion has been found to be helpful in classifying the patient. When scintigraphy is not available, an elevation of hydroxyproline excretion, together with an elevation of Ca/cr ratio or alkaline phosphatase activity, may pre-date by several months the radiological demonstration of osseous metastases.
 ...
PMID:Relevance of hydroxyproline excretion to bone metastasis in breast cancer. 97 1


1 2 3 4 5 6 7 8 9 10 Next >>